From Yahoo Finance: 2025-05-20 10:55:00

Wells Fargo upgraded RxSight Inc. (NASDAQ: RXST) from Equal Weight to Overweight, setting a price target of $25 due to attractive valuation. The company leads in light-adjustable lens technology for cataract surgery, with full regulatory approval in South Korea and UK anticipated in Q2 2025.

RxSight’s first-mover advantage and decade-plus journey to bring LAL technology to the US market positions it ahead of competitors. The company’s RxSight system allows customization and enhancement of visual acuity post-cataract surgery, contributing to market growth potential and differentiated product offerings.

RxSight Inc. (NASDAQ: RXST) is a commercial-stage medical tech company specializing in light-adjustable intraocular lenses used in cataract surgery in the US. The company is advancing its technology with software updates for its Light Delivery Device procedures and expects regulatory approval in the UK in Q2 2025.

While Wells Fargo sees potential in RXST, they believe other AI stocks offer greater returns with limited downside risk. They recommend exploring AI stocks with higher upside potential. The company’s innovative approach to cataract surgery technology positions it as a key player in a competitive market.

Read more: Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued